

Edgar Filing: VASOMEDICAL INC - Form 8-K

VASOMEDICAL INC  
Form 8-K  
October 25, 2005

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report: October 19, 2005  
(Date of earliest event reported)

VASOMEDICAL, INC.  
(Exact name of registrant as specified in its charter)

Delaware	0-18105	11-2871434
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)
180 Linden Avenue, Westbury, New York		11590
-----		-----
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number including area code (516) 997-4600  
-----

Not applicable  
-----

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to  
simultaneously satisfy the filing obligation of the registrant under any of the  
following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR  
230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR  
240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange  
Act

Pre-commencement communications pursuant to Rule 13e-4c under the Exchange  
Act (17 CFR 240.13e-4c)

Item 8.01 Other Events

Edgar Filing: VASOMEDICAL INC - Form 8-K

The Company has been informed that the report of the PEECH Clinical Study has been accepted for publication in a major peer-reviewed medical journal. The journal requires that the contents of the report be held confidential until its publication. Therefore, no additional information concerning this article will be provided until such time as it is published.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VASOMEDICAL, INC.

By: /s/ Thomas Glover

-----  
Thomas Glover  
President and Chief Executive Officer

Dated: October 24, 2005